Stelic Institute & Co..


dsa1.jpg dsa3.jpg

ac8.jpg  ac5.jpg ac6.jpg ac7.jpg

bb1.jpg  o1.jpg


Apr 08, 2014
Data from STAM model was presented in AACR 2014*, San Diego.
* AACR 2014: The 105th Annual Meeting of the American Association for Cancer Research
Feb 03, 2014
Stelic launched new contracting service “Histopathology and Imaging analysis services”
Nov 04, 2013
Stelic announced that Tobira Therapeutics Inc. presented the study results on anti-fibrotic activity of cenicriviroc using STAM model at The Liver Meeting 2013 (the 64th annual meeting of the AASLD) in Washington, DC. (Abstract ID #30).
Sep 19, 2013
Stelic announced that Boehringer Ingelheim GmbH has published the results of pharmacology studies using STAM model in Medical Molecular Morphology: “Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis” (Publisher: Springer)
Sep 11, 2013
Data from STAM model were presented in The 86th Annual Meeting of the Japanese Biochemical Society, Yokohama.
Aug 05, 2013
Stelic announced that F. Hoffmann-La Roche AG presented pharmacology study results using STAM model in 2013 FASEB Summer Research Conference “Lysophospholipid and Other Related Mediators - From Bench to Clinic”, Niseko (Hokkaido, JAPAN).
Apr 01, 2013
Data from STAM model was presented in The 133rd annual meeting of The Pharmaceutical Society of Japan, Yokohama.
Mar 20, 2013
Dr. Hiroyuki Yoneyama, Representative Director commented about NASH in Hepatology (March 2013).Titled “From NAFLD to NASH to fibrosis to HCC: Role of dendritic cell (DC) populations in the liver.”
Mar 05, 2013
Stelic’s preclinical CRO client Galectin Therapeutics Inc. (NASDAQ: GALT) received positive feedback from the FDA to progress into first-in-man, Phase 1 clinical trials of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease) with advanced fibrosis. 
More information can be found at “Preclinical CRO case studies
Feb 22, 2013
Published the article for mouse model of NASH-HCC (STAM Model) on Medical Molecular Morphology. Titled “A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma.” (Published by Springer)
Nov 13, 2012
Data from STAM model were presented by several companies and universities in AASLD 2012*, Boston.
*AASLD 2012: The 63rd Annual Meeting of the American Association for the Study of Liver Diseases
Oct 31, 2012
Stelic’s preclinical CRO client Phenex Pharmaceuticals, Inc. completed of Phase 1 clinical trial of FXR-Agonist Px-102.
Aug 10, 2012
Launched three new contract research services for development anti-fibrotic drugs:
Jul 02, 2012
Accepted the article for mouse model of NASH-HCC (STAM Model) in “Medical Molecular Morphology”.
Jun 01, 2012
Started to sell liver and blood samples of NASH-HCC mouse model (STAM Model), for R & D program such as evaluation of pathogenesis, development of biomarkers, etc.
May 23, 2012
Stelic had two presentations about our STAM model in DDW 2012,
SanDiego: “Clinical relevance between human and STAM model”.
Aug 22, 2011
“News and Education”, new website contents about research and development of NASH are released.
Nov 18, 2010
Data from pharmacological clinical trial of STAM mice were published at an international conference "NASH 2010": the Ninth JSH Single Topic Conference.
Jul 30, 2010
Stelic signed collaborative research agreement with Hokkaido University in carbohydrate research field.
May 10, 2010
Stelic launched new contracting service "Liver histology scoring".
Dec 24, 2009
Received top-grade grant from JST
Subject:“The development of RNA interference-based therapeutics for Crohn's disease stricture.”
JST; Japan Science and Technology Agency
Aug 27, 2009
Received grant from NEDO : “Grant for Application of Industrial Technology Innovation”.
Jul 02, 2009
Stelic won cum laude recognition for a poster presentation in the 17th Japan Digestive Disease Week 2009(JDDW 2009). - Kyoto: Thursday, October 15, 2009
Subject:“Establishment of a novel NASH model mice representative human pathological condition”
Apr 01, 2009
Stelic announced the launch of contracting services for hepatic cancer (HCC) therapeutic evaluation, using Stelic’s novel NASH-HCC Mouse Model.



Stelic Institute & Co., Inc.
1-9-15 Higashi Azabu Minato-City,
Tokyo ,106-0044 Japan
Tel: +81-3-3560-2621
Fax: +81-3-3560-2620